Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 12, 2008, Pages 4251-4257

  Marcelin, Anne Geneviève ^a,b   Flandre, Philippe ^c   Molina, Jean Michel ^d,e   Katlama, Christine ^b,c   Yeni, Patrick ^d,f   Raffi, Francois ^g   Antoun, Zeina ^h   Ait Khaled, Mounir ⁱ   Calvez, Vincent ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f BICHAT HOSPITAL   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h Epidemiology Department   (France)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE PLUS RITONAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; ENFUVIRTIDE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL TRIAL; CODON; DRUG RESPONSE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RESISTANCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRAL GENETICS;

ADULT; ANTI-HIV AGENTS; CARBAMATES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; PHOSPHORIC ACID ESTERS; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 57049155623     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00514-08     Document Type: Article

References (23)

1. DeJesus, E., A. Lamarca, M. Sension, C. Beltran, and P. Yeni. 2003. Abstr. 10th Conf. Retroviruses Opportun. Infect., abstr. 178.
2. Elston, R., S. White, P. Yates, F. Xu, N. Richards, S. Sharp, M. B. Wire, and M. Tisdale. 2004. Abstr. XIII Int. HIV Drug Resist. Workshop, abstr. 115.
3. Elston, R., P. Yates, M. Tisdale, N. Richards, S. White, and E. DeJesus. 2004. Abstr. XV Int. AIDS Conf., abstr. MoOrB1055.
4. Elston, R., S. Randall, F. Xu, W. Harris, V. Manohitharajah, M. Maguire, A. Rakik, M. Ait-Khaled, D. S. Stein, M. Tisdale, and W. Snowden. 2001. Abstr. 2nd Int. Workshop Clin. Pharmacol. HIV Ther., abstr. 5.
5. Eron, J., Jr., P. Yeni, J. Gathe, Jr., V. Estrada, E. DeJesus, S. Staszewski, P. Lackey, C. Katlama, B. Young, L. Yau, D. Sutherland-Phillips, P. Wannamaker, C. Vavro, L. Patel, J. Yeo, and M. Shaefer. 2006. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368:476-482.
6. Flandre, P., A. G. Marcelin, J. Pavie, N. Shmidely, M. Wirden, O. Lada, M. C. Bernard, J. M. Molina, and V. Calvez. 2005. Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. Antivir. Ther. 10:479-487.
7. Flandre, P., and J. O'Quigley. 2007. Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection. Stat. Med. 26:4441-4454.
8. Gathe, J. C., Jr., P. Ive, R. Wood, D. Schurmann, N. C. Bellos, E. DeJesus, A. Gladysz, C. Garris, and J. Yeo. 2004. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18:1529-1537.
9. Johnson, V. A., F. Brun-Vezinet, B. Clotet, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2006. Update of the drug resistance mutations in HIV-1: fall 2006. Top. HIV Med. 14:125-130.
10. Jonckheere, A. R. 1954. A distribution-free k-sample test against ordered alternatives. Biometrika 41:133-145.
11. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, J. Sylte, B. Richards, B. Bernstein, R. Rode, and E. Sun. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7:165-174.
12. MacManus, S., P. J. Yates. R. C. Elston. S. White, N. Richards, and W. Snowden. 2004. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 18:651-655.
13. Maguire, M., D. Shortino, A. Klein, W. Harris, V. Manohitharajah, M. Tisdale, R. Elston, J. Yeo, S. Randall, F. Xu, H. Parker, J. May, and W. Snowden. 2002. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob. Agents Chemother. 46:731-738.
14. Marcelin, A. G., P. Flandre, C. de Mendoza, B. Roquebert, G. Peytavin, L. Valer, M. Wirden, S. Abbas, C. Katlama, V. Soriano, and V. Calvez. 2007. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. Antivir. Ther. 12:247-252.
15. Marcelin, A.-G., P. Flandre, J. Pavie, N. Schmidely, M. Wirden, O. Lada, D. Chiche, J.-M. Molina, and V. Calvez. 2005. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob. Agents Chemother. 49:1739-1744.
16. Marcelin, A.-G., P. Flandre, J.-M. Molina, C. Katlama, P. Yéni, F. Raffi, Z. Antoun, M. Ait-Khaled, and V. Calvez. 2007. Abstr. 14th Conf. Retroviruses Opportun. Infect., abstr. 608.
17. Masquelier, B., K. L. Assoumou, D. Descamps, L. Bocket, J. Cottalorda, A. Ruffault, A. G. Marcelin, L. Morand-Joubert, C. Tamalet, C. Charpentier, G. Peytavin, Z. Antoun, F. Brun-Vezinet, and D. Costagliola. 2008. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. J. Antimicrob. Chemother. 61:1362-1368.
18. Murphy, M. D., G. I. Marousek, and S. Chou. 2004. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M. J. Clin. Virol. 30:62-67.
19. Parkin, N. T., C. Chappey, and C. J. Petropoulos. 2003. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 17:955-961.
20. Pellegrin, I., D. Breilh, G. Coureau, S. Boucher, D. Neau, P. Merel, D. Lacoste, H. Fleury, M. C. Saux, J. L. Pellegrin, E. Lazaro, F. Dabis, and R. Thiebaut. 2007. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral- experienced patients. Antimicrob. Agents Chemother. 51:1473-1480.
21. Quercia, R., E. Garnier, V. Ferre, P. Morineau, B. Bonnet, C. Soulard, and F. Raffi. 2005. Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up. HIV Clin. Trials 6:73-80.
22. Ross, L., C. Vavro, B. Wine, and Q. Liao. 2006. Fosamprenavir clinical study meta-analysis in ART-naive subjects: rare occurrence of virologic failure and selection of protease-associated mutations. HIV Clin. Trials 7:334-338.
23. Vora, S., A. G. Marcelin, H. F. Gunthard, P. Flandre, H. H. Hirsch, B. Masquelier, A. Zinkernagel, G. Peytavin, V. Calvez, L. Perrin, and S. Yerly. 2006. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 20:35-40.